Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients male or female between 18 and 80 years of age
Patients with mild to moderate essential hypertension
Patients diagnosed with hypertension that are not currently taking antihypertensive medication or previously diagnosed hypertensive patients who are uncontrolled with their current treatment
You may not be if
Pre-menopausal women who have no birth control, who are pregnant or nursing
Patients with advanced hepatic impairment or advanced renal impairment
Patients with New York Heart Association (NYHA) functional class III or IV congestive heart failure (CHF), unstable angina, acute myocardial infarction, heart surgery or stroke within the previous six months
Patients with any type of relevant arrhythmia according to the assessment of the investigator
Patients with any valvular disease with hemodynamic repercussion
Patients receiving chronic administration of oral anticoagulants or digoxin
Patients with known hypersensitivity to any component in the formulation of Micardis®, Telmisartan or Micardis Plus®, Telmisartan hydrochlorothiazide
Patients with previous history of angioedema associated with angiotensin converting enzyme (ACE) inhibitors
Patients with severe, uncontrolled hypertension or any form of secondary hypertension
Patients with any other clinical conditions which, in the opinion of the investigator, would not allow for the safe completion of the protocol
Clareo Health | A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
